Mesoblast Stock Price, News & Analysis (NASDAQ:MESO)

$5.46 0.08 (1.49 %)
(As of 12/14/2017 09:55 AM ET)
Previous Close$5.38
Today's Range$5.36 - $5.50
52-Week Range$4.80 - $12.50
Volume46,100 shs
Average Volume31,205 shs
Market Capitalization$460.77 million
P/E RatioN/A
Dividend YieldN/A
Beta2.68

About Mesoblast (NASDAQ:MESO)

Mesoblast logoMesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

Receive MESO News and Ratings via Email

Sign-up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MESO
CUSIPN/A
Phone61-3-9639-6036

Debt

Debt-to-Equity RatioN/A
Current Ratio3.53%
Quick Ratio3.53%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.41 million
Price / Sales194.02
Cash FlowN/A
Price / CashN/A
Book Value$6.03 per share
Price / Book0.91

Profitability

Trailing EPS($0.78)
Net Income$-76,810,000.00
Net Margins-2,006.86%
Return on Equity-12.04%
Return on Assets-9.60%

Miscellaneous

Employees108
Outstanding Shares85,640,000

Mesoblast (NASDAQ:MESO) Frequently Asked Questions

What is Mesoblast's stock symbol?

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

When will Mesoblast make its next earnings announcement?

Mesoblast is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for Mesoblast.

Where is Mesoblast's stock going? Where will Mesoblast's stock price be in 2017?

6 equities research analysts have issued 1-year target prices for Mesoblast's shares. Their predictions range from $8.50 to $20.00. On average, they expect Mesoblast's stock price to reach $14.25 in the next twelve months. View Analyst Ratings for Mesoblast.

What are Wall Street analysts saying about Mesoblast stock?

Here are some recent quotes from research analysts about Mesoblast stock:

  • 1. According to Zacks Investment Research, "Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. " (11/16/2017)
  • 2. Maxim Group analysts commented, "Mesoblast reported year-end (FYE June 30) with a net loss of $77M and ended the period with $46M in cash. The company completed a $40M raise on August 29, 2017 and currently has $84M in cash on the balance sheet." (8/30/2017)
  • 3. Cantor Fitzgerald analysts commented, "Accelerating Chronic Heart Failure (CHF). Mesoblast recently outlined its plans to seek a potential accelerated approval pathway for its MPC-150-IM product in patients with advanced cardiac heart failure. Based on the significant unmet need and serious complications of the disease, the company believes its 159-patient Phase 2b study with end-stage (Class IV) CHF patients that require left ventricular device (LVAD) assistance could support an accelerated approval. Completion of enrollment is imminent, and top-line data from the study are expected in 1Q18. The primary endpoint of the study will assess the number of times patients are able to undergo weaning off LVAD assistance. Enrolling in Advanced CHF. Mesoblast is also conducting a large 600-patient Phase 3 study in advanced (Class II/III) CHF patients that could serve as a confirmatory study and has enrolled over 400 patients so far. This study will assess recurrent, non-fatal, HF-related major adverse cardiac events between MPC-treated and sham-treated patients. Data are expected to be released in 2019. Attractive Markets. We estimate a large, multi-billion-dollar market for Mesoblast’s cell portfolio (combined royalties of ~$6 billion) when it reaches peak market penetration." (8/30/2017)

Who are some of Mesoblast's key competitors?

Who are Mesoblast's key executives?

Mesoblast's management team includes the folowing people:

  • Silviu Itescu, Chief Executive Officer, Executive Director
  • William A. Burns, Vice Chairman of the Board
  • Paul Hodgkinson, Group Chief Financial Officer
  • Peter Howard, General Counsel, Corporate Executive
  • John McMannis Ph.D., Head of Manufacturing
  • Paul Simmons Ph.D., Head of Research and New Product Development
  • Donna Skerrett M.D., Chief Medical Officer
  • Geraldine Storton MBA, Head of Regulatory Affairs and Quality Management
  • Charlie Harrison, Company Secretary
  • Brian Jamieson, Independent Non-Executive Chairman of the Board

When did Mesoblast IPO?

(MESO) raised $69 million in an initial public offering on Friday, November 13th 2015. The company issued 5,700,000 shares at a price of $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

How do I buy Mesoblast stock?

Shares of Mesoblast can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mesoblast's stock price today?

One share of Mesoblast stock can currently be purchased for approximately $5.46.

How big of a company is Mesoblast?

Mesoblast has a market capitalization of $460.77 million and generates $2.41 million in revenue each year. The company earns $-76,810,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. Mesoblast employs 108 workers across the globe.

How can I contact Mesoblast?

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected]


MarketBeat Community Rating for Mesoblast (MESO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  126 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  211
MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mesoblast (NASDAQ:MESO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.572.572.572.33
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.25$14.25$14.25$10.50
Price Target Upside: 163.89% upside163.89% upside128.37% upside29.47% upside

Mesoblast (NASDAQ:MESO) Consensus Price Target History

Price Target History for Mesoblast (NASDAQ:MESO)

Mesoblast (NASDAQ:MESO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2017Maxim GroupSet Price TargetBuy$14.00N/AView Rating Details
11/14/2017OppenheimerSet Price TargetBuy$16.00N/AView Rating Details
8/31/2017CIBCInitiated CoverageOutperform -> Outperform$16.00HighView Rating Details
8/30/2017Cantor FitzgeraldReiterated RatingBuy$20.00HighView Rating Details
7/18/2017Credit Suisse GroupSet Price TargetHold$11.00LowView Rating Details
4/3/2017ScotiabankReiterated RatingHold$8.50LowView Rating Details
6/15/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
2/25/2016Chardan CapitalReiterated RatingHoldN/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Earnings History for Mesoblast (NASDAQ:MESO)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Mesoblast (NASDAQ:MESO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.57)
2019 EPS Consensus Estimate: ($0.54)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181($0.19)($0.19)($0.19)
Q3 20181($0.19)($0.19)($0.19)
Q4 20181($0.19)($0.19)($0.19)
Q1 20191($0.19)($0.19)($0.19)
Q2 20191($0.20)($0.20)($0.20)
Q3 20191($0.21)($0.21)($0.21)
Q4 20191$0.06$0.06$0.06
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Mesoblast (NASDAQ:MESO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Mesoblast (NASDAQ MESO)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Mesoblast (NASDAQ MESO) News Headlines

Source:
DateHeadline
Mesoblast (MESO) versus Its Rivals Head-To-Head AnalysisMesoblast (MESO) versus Its Rivals Head-To-Head Analysis
www.americanbankingnews.com - December 13 at 1:30 AM
Mesoblast Named Global Technology Leader in Cell Therapy Industry - Business Wire (press release)Mesoblast Named Global Technology Leader in Cell Therapy Industry - Business Wire (press release)
www.businesswire.com - December 12 at 10:05 AM
Mesoblast (MESO) and GenVec (GNVC) Head-To-Head AnalysisMesoblast (MESO) and GenVec (GNVC) Head-To-Head Analysis
www.americanbankingnews.com - December 12 at 3:24 AM
Contrasting Portola Pharmaceuticals (PTLA) & Mesoblast (MESO)Contrasting Portola Pharmaceuticals (PTLA) & Mesoblast (MESO)
www.americanbankingnews.com - December 10 at 3:26 AM
Mesoblast Named Global Technology Leader in Cell Therapy Industry - GlobeNewswire (press release)Mesoblast Named Global Technology Leader in Cell Therapy Industry - GlobeNewswire (press release)
www.globenewswire.com - December 7 at 5:36 PM
Mesoblast Named Global Technology Leader in Cell Therapy IndustryMesoblast Named Global Technology Leader in Cell Therapy Industry
finance.yahoo.com - December 7 at 5:36 PM
Mesoblast Limited (MESO) to Post FY2018 Earnings of ($0.80) Per Share, Cantor Fitzgerald ForecastsMesoblast Limited (MESO) to Post FY2018 Earnings of ($0.80) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - November 22 at 1:58 PM
Financial Review: Mesoblast Limited (MESO) vs. Its PeersFinancial Review: Mesoblast Limited (MESO) vs. Its Peers
www.americanbankingnews.com - November 21 at 2:12 PM
Mesoblast Limited (MESO) Given Consensus Recommendation of "Hold" by AnalystsMesoblast Limited (MESO) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 21 at 8:24 AM
Mesoblast Limited (MESO) Given a $16.00 Price Target by Oppenheimer Holdings, Inc. AnalystsMesoblast Limited (MESO) Given a $16.00 Price Target by Oppenheimer Holdings, Inc. Analysts
www.americanbankingnews.com - November 19 at 10:20 PM
Maxim Group Analysts Give Mesoblast Limited (MESO) a $14.00 Price TargetMaxim Group Analysts Give Mesoblast Limited (MESO) a $14.00 Price Target
www.americanbankingnews.com - November 19 at 5:38 PM
Zacks Investment Research Lowers Mesoblast Limited (MESO) to Strong SellZacks Investment Research Lowers Mesoblast Limited (MESO) to Strong Sell
www.americanbankingnews.com - November 18 at 10:52 PM
Mesoblast Limited Forecasted to Earn Q2 2018 Earnings of ($0.19) Per Share (MESO)Mesoblast Limited Forecasted to Earn Q2 2018 Earnings of ($0.19) Per Share (MESO)
www.americanbankingnews.com - November 17 at 11:52 PM
Chairman’s Address to the Mesoblast 2017 Annual General MeetingChairman’s Address to the Mesoblast 2017 Annual General Meeting
finance.yahoo.com - November 17 at 3:59 PM
Mesoblast Operational Highlights and Financial Results for the First Quarter Ended September 30, 2017 - GlobeNewswire (press release)Mesoblast Operational Highlights and Financial Results for the First Quarter Ended September 30, 2017 - GlobeNewswire (press release)
globenewswire.com - November 15 at 6:20 AM
Mesoblast to Host First Quarter Financial Results Webcast and Conference Call - GlobeNewswire (press release)Mesoblast to Host First Quarter Financial Results Webcast and Conference Call - GlobeNewswire (press release)
globenewswire.com - November 15 at 6:20 AM
Why Mesoblast limited remains a capital sinkhole - Motley Fool AustraliaWhy Mesoblast limited remains a capital sinkhole - Motley Fool Australia
www.fool.com.au - November 15 at 6:20 AM
Reviewing Mesoblast Limited (MESO) & Protagonist Therapeutics (PTGX)Reviewing Mesoblast Limited (MESO) & Protagonist Therapeutics (PTGX)
www.americanbankingnews.com - November 14 at 1:36 PM
Mesoblast to Host First Quarter Financial Results Webcast and Conference CallMesoblast to Host First Quarter Financial Results Webcast and Conference Call
feeds.benzinga.com - November 13 at 5:49 PM
Mesabi Trust (MESO) Phase 2 RA Trial Shows Early and Durable EffectsMesabi Trust (MESO) Phase 2 RA Trial Shows Early and Durable Effects
www.streetinsider.com - November 12 at 6:21 AM
Mesoblasts MPC therapy shows durable effect in mid-stage RA study; shares ahead 2%Mesoblast's MPC therapy shows durable effect in mid-stage RA study; shares ahead 2%
seekingalpha.com - November 12 at 6:21 AM
BRIEF-MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTSBRIEF-MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTS
www.reuters.com - November 12 at 6:21 AM
ETFs with exposure to Mesoblast Ltd. : November 6, 2017ETFs with exposure to Mesoblast Ltd. : November 6, 2017
finance.yahoo.com - November 7 at 6:44 AM
Mesoblast Limited (MESO) Receives Average Recommendation of "Hold" from BrokeragesMesoblast Limited (MESO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 27 at 7:58 AM
Here’s why the Mesoblast limited share price is getting slammed todayHere’s why the Mesoblast limited share price is getting slammed today
www.fool.com.au - October 25 at 7:12 AM
ETFs with exposure to Mesoblast Ltd. : October 23, 2017ETFs with exposure to Mesoblast Ltd. : October 23, 2017
finance.yahoo.com - October 24 at 5:30 AM
Critical Analysis: Chromadex Corp (CDXC) vs. Mesoblast Limited (MESO)Critical Analysis: Chromadex Corp (CDXC) vs. Mesoblast Limited (MESO)
www.americanbankingnews.com - October 19 at 8:28 PM
Head to Head Analysis: Mesoblast Limited (MESO) versus Fibrocell Science (FCSC)Head to Head Analysis: Mesoblast Limited (MESO) versus Fibrocell Science (FCSC)
www.americanbankingnews.com - October 16 at 10:30 AM
ETFs with exposure to Mesoblast Ltd. : October 9, 2017ETFs with exposure to Mesoblast Ltd. : October 9, 2017
finance.yahoo.com - October 9 at 4:06 PM
Mesoblast Ltd. :MESO-US: Earnings Analysis: Q4, 2017 By the Numbers : October 6, 2017Mesoblast Ltd. :MESO-US: Earnings Analysis: Q4, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 10:25 AM
Mesoblast Limited (MESO) Upgraded to "Buy" by Zacks Investment ResearchMesoblast Limited (MESO) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - October 5 at 12:26 AM
Global Cell Therapy Market Report 2017-2021: Proliferation of Strategic Alliances and Royalty PaymentsGlobal Cell Therapy Market Report 2017-2021: Proliferation of Strategic Alliances and Royalty Payments
www.finanznachrichten.de - October 4 at 7:33 AM
Mesoblast Limited (MESO) Receives Consensus Rating of "Hold" from AnalystsMesoblast Limited (MESO) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - October 2 at 4:32 AM
Mesoblast Limiteds (MESO) "Buy" Rating Reaffirmed at Maxim GroupMesoblast Limited's (MESO) "Buy" Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - October 1 at 7:40 PM
Research Analysts Offer Predictions for Mesoblast Limiteds Q1 2019 Earnings (MESO)Research Analysts Offer Predictions for Mesoblast Limited's Q1 2019 Earnings (MESO)
www.americanbankingnews.com - September 29 at 1:52 PM
Mesoblast Becomes Oversold (MESO)Mesoblast Becomes Oversold (MESO)
www.thestreet.com - September 28 at 12:52 PM
Clinical Trial of Mesoblast’s Cell Therapy in End-Stage Heart Failure Patients Completes EnrollmentClinical Trial of Mesoblast’s Cell Therapy in End-Stage Heart Failure Patients Completes Enrollment
globenewswire.com - September 28 at 12:52 PM
Mesoblast Limited (MESO) Given Consensus Recommendation of "Hold" by BrokeragesMesoblast Limited (MESO) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 7 at 4:46 AM
ETFs with exposure to Mesoblast Ltd. : September 6, 2017ETFs with exposure to Mesoblast Ltd. : September 6, 2017
finance.yahoo.com - September 5 at 10:09 PM
Head-To-Head Contrast: Mesoblast Limited (MESO) versus Organovo Holdings (ONVO)Head-To-Head Contrast: Mesoblast Limited (MESO) versus Organovo Holdings (ONVO)
www.americanbankingnews.com - September 4 at 4:06 PM
Mesoblast Ltd. :MESO-US: Earnings Analysis: 2017 By the Numbers : September 1, 2017Mesoblast Ltd. :MESO-US: Earnings Analysis: 2017 By the Numbers : September 1, 2017
finance.yahoo.com - September 2 at 6:14 AM
Mesoblast Ltd. :MESO-US: Earnings Analysis: 2017 By the Numbers : September 1, 2017Mesoblast Ltd. :MESO-US: Earnings Analysis: 2017 By the Numbers : September 1, 2017
finance.yahoo.com - September 2 at 6:14 AM
Mesoblast Limited to Post FY2018 Earnings of ($1.16) Per Share, Cantor Fitzgerald Forecasts (MESO)Mesoblast Limited to Post FY2018 Earnings of ($1.16) Per Share, Cantor Fitzgerald Forecasts (MESO)
www.americanbankingnews.com - September 1 at 11:52 AM
CIBC Initiates Coverage on Mesoblast limited (MESO)CIBC Initiates Coverage on Mesoblast limited (MESO)
www.americanbankingnews.com - August 31 at 2:32 PM
Mesoblast limited (MESO) Research Coverage Started at Oppenheimer Holdings, Inc.Mesoblast limited (MESO) Research Coverage Started at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - August 31 at 9:50 AM
UPDATE: Oppenheimer Starts Mesoblast Limited (MESO) at Outperform - StreetInsider.comUPDATE: Oppenheimer Starts Mesoblast Limited (MESO) at Outperform - StreetInsider.com
www.streetinsider.com - August 31 at 7:11 AM
Mesoblast Limited (MESO) Given a $14.00 Price Target at Maxim GroupMesoblast Limited (MESO) Given a $14.00 Price Target at Maxim Group
www.americanbankingnews.com - August 30 at 11:16 AM
Mesoblast (MESO) Says it Completed Institutional Entitlement Offer for Fully Underwritten A$50.7M Capital Raise - StreetInsider.comMesoblast (MESO) Says it Completed Institutional Entitlement Offer for Fully Underwritten A$50.7M Capital Raise - StreetInsider.com
www.streetinsider.com - August 30 at 6:29 AM
Mesoblast Operational Highlights and Financial Results for the Fourth Quarter and for the Year Ended 30 June 2017 - GlobeNewswire (press release)Mesoblast Operational Highlights and Financial Results for the Fourth Quarter and for the Year Ended 30 June 2017 - GlobeNewswire (press release)
globenewswire.com - August 30 at 6:29 AM
Mesoblast Limited looks a long way from take off - Motley Fool AustraliaMesoblast Limited looks a long way from take off - Motley Fool Australia
www.fool.com.au - August 30 at 6:29 AM

SEC Filings

Mesoblast (NASDAQ:MESO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Mesoblast (NASDAQ MESO) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.